Hi @shwibble. I'd be somewhat cautious thinking about valuing a company by simply comparing revenue to market cap. At today's 0.9c share price, the company's market cap is $22.4M. So if you were going to buy the company outright, for $22.4M you'd be getting:
- $19.4M in revenues and $3.9m in cash and undrawn loan facilities (prior to the most recent CR)
- However you're also assuming responsibility for -$31.2M in operating expenses p/a (of which -$12.8M is spent on staff costs alone)
Yes, they have raised some more cash recently, and are suggesting they will reduce the cash expenses by ~$4M p/a, but by that estimate they'll chew up around -$27M in expenses next year. So they need to grow revenues by around 40% just to break even by end of FY23. That growth needs to be organic; as I'm sure holders are now aware, growth by acquisition is expensive and often doesn't deliver shareholder value, unless large cost-cutting synergies can be realised. Cheers
- Forums
- ASX - By Stock
- KDY
- Ann: DW8 Secures Institutional Funding Launches Entitlement Offer
Ann: DW8 Secures Institutional Funding Launches Entitlement Offer, page-346
-
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KDY (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.834M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
KDY (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online